Earnings Call Summary | MediWound(MDWD.US) Q4 2023 Earnings Conference
Earnings Call Summary | MediWound(MDWD.US) Q4 2023 Earnings Conference
The following is a summary of the MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript:
以下是MediWound Ltd.（MDWD）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
MediWound reported full year 2023 revenue of $19 million, driven largely by sales of NexoBrid in the U.S., Japan, and India.
Projection for the fiscal year 2024 is estimated around $24 million and the revenues are expected to hit $39 million in 2026.
The Q1 2023 revenue was $5.3 million, a decrease from Q1 2022's $11.6 million in revenue. The primary reason was the absence of the BLA approval milestone payment from Vericel.
The company triggered an operating loss of $3.9 million in Q1 2023, compared to an operating profit of $2.1 million in Q1 2022.
Net loss for Q1 2023 was $1.7 million or $0.19 per share, a decrease from a net loss of $7.5 million in Q1 2022 due to a favorable adjustment from the revaluation of warrants.
MediWound報告稱，2023年全年收入爲1900萬美元，這主要是由NexoBrid在美國、日本和印度的銷售推動的。
預計2024財年約爲2400萬美元，收入預計將在2026年達到3,900萬美元。
2023年第一季度的收入爲530萬美元，較2022年第一季度的1160萬美元收入有所下降。主要原因是Vericel沒有按照BLA的批准里程碑付款。
該公司在2023年第一季度引發了390萬美元的營業虧損，而2022年第一季度的營業利潤爲210萬美元。
由於認股權證重估進行了有利的調整，2023年第一季度的淨虧損爲170萬美元，合每股虧損0.19美元，低於2022年第一季度的750萬美元淨虧損。
Business Progress:
業務進展：
A Phase III trial for EscharEx is imminent. This product targets a $2 billion market and has shown superior performance over the current market leader in Phase II studies.
MediWound gained approval for NexoBrid for pediatric use in Europe and is under FDA review for similar approval in the U.S.
Expanded manufacturing facilities due to a surge in demand for NexoBrid. The expansion is scheduled to complete by mid-2024.
Research collaborations have been initiated with 3M, Mölnlycke, and MIMEDX for the upcoming EscharEx Phase III study.
The company secured a total of $23 million in R&D funding from the U.S. Department of Defense and from BARDA for the ongoing development of NexoBrid.
A project funded by DoD at $13 million is underway to transition the product to room temperature storage, which would simplify supply chains and administration.
Upcoming meetings with the FDA to discuss the development path and potential commercial activities under a license agreement with Vericel.
eSchareX的三期試驗迫在眉睫。該產品的目標市場規模爲20億美元，在II期研究中，其表現優於目前的市場領導者。
MediWound獲得了歐洲兒科用途的批准，並正在接受美國食品藥品管理局的審查，以獲得類似的批准。
由於對NexoBRID的需求激增，製造設施有所擴大。擴建計劃於2024年中期完成。
已經開始與3M、Monlycke和MIMEDX就即將到來的Escharex III期研究進行研究合作。
該公司從美國國防部和BARDA獲得了總計2300萬美元的研發資金，用於NexoBrid的持續開發。
一個由國防部資助的1300萬美元項目正在進行中，該項目旨在將該產品過渡到室溫存儲，這將簡化供應鏈和管理。
即將與美國食品藥品管理局舉行會議，討論與Vericel簽訂的許可協議下的開發路徑和潛在的商業活動。
More details: MediWound IR
更多詳情： MediWound 紅
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。